APMDHealthcare · Biotechnology

APMD Stock Forecast: Apnimed, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$27
−3.16% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 8 Aug 2026 — in the weakest quartile.

Market cap
$1.1B
Ticker Nerd rank
0 / 100
Median analyst target
Analysts covering
Total return, dividends reinvested
1W
+8.0%
From high
−3.2%
From low
+8.0%
$25
$28
Range since 31 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

APMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
44
Revisions
25
Accruals
8
Growth
8
Momentum
7
Quality
5
Value
4
Volatility
4
Issuance
2

Size (44): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership.

Wall Street

APMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

APMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Apnimed, Inc. (APMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
9.1×

Cheaper than 60% of US stocks

Price / sales
8.9×

Cheaper than 16% of US stocks

Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
9.4×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
2608.8%

Higher than 99% of US stocks

Earnings growth (YoY)
Gross margin
97.5%

Higher than 99% of US stocks

Operating margin
80.2%

Higher than 99% of US stocks

Net margin
−26.5%

Higher than 14% of US stocks

Returns & dividend
Return on equity
0.3%

Higher than 44% of US stocks

Return on assets
−1.3%

Higher than 39% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

APMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APMDApnimed, Inc.$1.1B
0
ANROAlto Neuroscience, Inc.$1.1B
48
SVRASavara, Inc.$1.1B
40
LXRXLexicon Pharmaceuticals, Inc.$1.1B
70
EYPTEyePoint, Inc.$1.1B
23
DRTSAlpha Tau Medical Ltd.$1.2B
15
CGEMCullinan Therapeutics, Inc.$1.1B
69
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

FAQ

Frequently asked questions about APMD stock

How does Ticker Nerd's model rank APMD?

As at 8 Aug 2026, Apnimed, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).

What is the APMD stock forecast for 2030?

No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business.

What does Apnimed, Inc. do?

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases.

Company

About Apnimed, Inc.

Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing novel oral therapies for sleep-related breathing diseases. Its core specialization is obstructive sleep apnea, where it aims to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep. Apnimed’s lead product candidate, AD109, also known as Oxnimbi, is an investigational, fixed-dose oral combination therapy designed as a once-daily, at-bedtime pill to improve upper airway muscle activity and oxygenation in adults with mild to severe obstructive sleep apnea. The company is advancing a broader portfolio of oral therapeutic candidates for sleep-related breathing disorders, positioning itself within the healthcare and biotechnology sectors at the intersection of drug discovery, clinical development, and sleep medicine. Apnimed primarily serves physicians, sleep centers, and healthcare systems seeking pharmacologic alternatives to device-based treatments, with an emphasis on convenient, non-invasive options. Founded in 2017 and headquartered in Cambridge, Massachusetts, Apnimed operates today as a specialized player in neurobiology-driven therapies for sleep-related breathing conditions.

CEO Mr. Kevin Robert Lind · 65 employees · United States · https://apnimed.com